EP3684336A4 - Méthodes et compositions pour le traitement d'une épidermolyse bulleuse - Google Patents

Méthodes et compositions pour le traitement d'une épidermolyse bulleuse Download PDF

Info

Publication number
EP3684336A4
EP3684336A4 EP18859166.3A EP18859166A EP3684336A4 EP 3684336 A4 EP3684336 A4 EP 3684336A4 EP 18859166 A EP18859166 A EP 18859166A EP 3684336 A4 EP3684336 A4 EP 3684336A4
Authority
EP
European Patent Office
Prior art keywords
compositions
treatment
methods
epidermolysis bullosa
bullosa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18859166.3A
Other languages
German (de)
English (en)
Other versions
EP3684336A1 (fr
Inventor
Evangelos V. BADIAVAS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miami
Original Assignee
University of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/712,294 external-priority patent/US20180104186A1/en
Application filed by University of Miami filed Critical University of Miami
Publication of EP3684336A1 publication Critical patent/EP3684336A1/fr
Publication of EP3684336A4 publication Critical patent/EP3684336A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Physical Water Treatments (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP18859166.3A 2017-09-22 2018-09-21 Méthodes et compositions pour le traitement d'une épidermolyse bulleuse Pending EP3684336A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/712,294 US20180104186A1 (en) 2013-03-13 2017-09-22 Methods and compositions for the treatment of epidermolysis bullosa
PCT/US2018/052213 WO2019060719A1 (fr) 2017-09-22 2018-09-21 Méthodes et compositions pour le traitement d'une épidermolyse bulleuse

Publications (2)

Publication Number Publication Date
EP3684336A1 EP3684336A1 (fr) 2020-07-29
EP3684336A4 true EP3684336A4 (fr) 2021-06-02

Family

ID=65810503

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18859166.3A Pending EP3684336A4 (fr) 2017-09-22 2018-09-21 Méthodes et compositions pour le traitement d'une épidermolyse bulleuse

Country Status (10)

Country Link
EP (1) EP3684336A4 (fr)
JP (1) JP7525396B2 (fr)
KR (1) KR20200088799A (fr)
CN (1) CN111182890A (fr)
AU (1) AU2018335788B2 (fr)
CA (1) CA3076610A1 (fr)
EA (1) EA202090814A1 (fr)
IL (1) IL273407A (fr)
MX (2) MX2020002777A (fr)
WO (1) WO2019060719A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10640464B2 (en) 2011-01-03 2020-05-05 The William M. Yarbrough Foundation Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
KR102125567B1 (ko) * 2019-07-02 2020-06-22 한양대학교 에리카산학협력단 식물 엑소좀의 대량 생산 방법
AU2020459825A1 (en) * 2020-07-22 2023-03-16 Osaka University Therapeutic agent for dystrophic epidermolysis bullosa
MX2023001927A (es) * 2020-08-21 2023-03-09 Univ Miami Composiciones y metodos de tratamiento usando microvesiculas de celulas madre mesenquimaticas derivadas de medula osea.
EP3971440B1 (fr) 2020-09-21 2023-12-27 Brembo S.p.A. Bande de freinage d'un disque de frein à disque et disque de frein à disque
WO2023018891A1 (fr) * 2021-08-12 2023-02-16 Onconova Therapeutics, Inc. Méthodes et compositions pour traiter le cancer
EP4415732A1 (fr) * 2021-10-12 2024-08-21 Eliksa Therapeutics, Inc. Méthodes de traitement de l'épidermolyse bulleuse avec des compositions de liquide amniotique acellulaire

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138878A1 (fr) * 2014-03-13 2015-09-17 Research Institute At Nationwide Children's Hospital, Inc. Procédés d'administration d'un facteur de croissance épidermique de liaison à l'héparine à l'aide d'exosomes générés par des cellules souches
WO2017123022A1 (fr) * 2016-01-12 2017-07-20 주식회사 강스템바이오텍 Exosome dérivé de cellules souches contenant une quantité importante de facteurs de croissance

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2972193T (pt) * 2013-03-13 2020-04-23 Univ Miami Método para isolamento e purificação de microvesículas de sobrenadantes de cultura celular e fluidos biológicos
WO2015038075A1 (fr) 2013-09-16 2015-03-19 Agency For Science, Technology And Research Procédé
WO2016172598A1 (fr) * 2015-04-22 2016-10-27 The Broad Institute Inc. Exosomes et leurs utilisations
WO2017122095A1 (fr) * 2016-01-15 2017-07-20 Orbsen Therapeutics Limited Compositions d'exosomes à base de sdc2 et leurs procédés d'isolement et d'utilisation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138878A1 (fr) * 2014-03-13 2015-09-17 Research Institute At Nationwide Children's Hospital, Inc. Procédés d'administration d'un facteur de croissance épidermique de liaison à l'héparine à l'aide d'exosomes générés par des cellules souches
WO2017123022A1 (fr) * 2016-01-12 2017-07-20 주식회사 강스템바이오텍 Exosome dérivé de cellules souches contenant une quantité importante de facteurs de croissance
US20190133922A1 (en) * 2016-01-12 2019-05-09 Kangstem Biotech Co., Ltd. Stem Cell-Derived Exosomes Containing a High Amount of Growth Factors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DINH HA ET AL: "Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges", ACTA PHARMACEUTICA SINICA B, vol. 6, no. 4, 1 July 2016 (2016-07-01), pages 287 - 296, XP055303644, ISSN: 2211-3835, DOI: 10.1016/j.apsb.2016.02.001 *
See also references of WO2019060719A1 *

Also Published As

Publication number Publication date
CA3076610A1 (fr) 2019-03-28
EP3684336A1 (fr) 2020-07-29
EA202090814A1 (ru) 2020-08-07
MX2020002777A (es) 2020-09-17
AU2018335788A1 (en) 2020-03-19
JP7525396B2 (ja) 2024-07-30
WO2019060719A1 (fr) 2019-03-28
JP2020534344A (ja) 2020-11-26
CN111182890A (zh) 2020-05-19
KR20200088799A (ko) 2020-07-23
MX2022015753A (es) 2023-01-19
AU2018335788B2 (en) 2024-08-15
IL273407A (en) 2020-05-31

Similar Documents

Publication Publication Date Title
EP3675882A4 (fr) Methodes et compositions pour le traitement de troubles associés au microbiome
EP3684336A4 (fr) Méthodes et compositions pour le traitement d'une épidermolyse bulleuse
EP3630072A4 (fr) Procédés et compositions pour le traitement d'une somnolence excessive
EP3607072A4 (fr) Compositions et méthodes de traitement de la phénylcétonurie
EP3347469A4 (fr) Méthodes et compositions pour le traitement du glaucome
EP3426250A4 (fr) Procédés de traitement
EP3373951A4 (fr) Méthodes et compositions pour le traitement d'une épidermolyse bulleuse
EP3602606A4 (fr) Procédés de traitement de surface et compositions à cet effet
EP3408344A4 (fr) Procédés et compositions de traitement de puits
EP3217795A4 (fr) Compositions et procédés de traitement avec des promédicaments du tizoxanide, un analogue ou un sel de celui-ci
EP3585817A4 (fr) Compositions et procédés de traitement du cancer
EP3448421A4 (fr) Procédés et compositions pour la prévention et le traitement d'adhérences chirurgicales
EP3538189A4 (fr) Compositions, dispositifs et méthodes pour le traitement de conditions médiées par un récepteur des opioides
EP3720421A4 (fr) Compositions et méthodes pour le traitement d'affections métaboliques
EP3634422A4 (fr) Méthodes de traitement de la leucodystrophie
EP3429584A4 (fr) Compositions et méthodes de traitement de la presbytie
EP3368048A4 (fr) Méthodes et compositions pour le traitement de l'amyloïdose
EP3310783A4 (fr) Procédés et compositions de prévention et de traitement de la perte d'audition
EP3643316A4 (fr) Agent de traitement de l' épidermolyse bulleuse
EP3423064A4 (fr) Formulations de testostérone et méthodes de traitement associées
EP3452044A4 (fr) Compositions et méthodes pour le traitement du cancer
EP3341006A4 (fr) Compositions et méthodes pour le traitement d'une lésion neurologique
EP3373922A4 (fr) Compositions et méthodes pour le traitement de l'homocystinurie
EP3349719A4 (fr) Compositions et méthodes destinées au traitement et à la prévention de la dermatite de rayonnement
EP3719032A4 (fr) Composition pour la prévention ou le traitement de la chute des cheveux

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200422

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40031789

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20210506

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/127 20060101AFI20210429BHEP

Ipc: A61K 35/28 20150101ALI20210429BHEP

Ipc: A61Q 19/00 20060101ALI20210429BHEP

Ipc: A61P 17/00 20060101ALI20210429BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230601

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS